drugset / Trial / NCT04153136

The ENCHANTMENT HIV Study

NCT04153136

Phase 2 Completed 39 enrolled Massachusetts General Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Persons with HIV, even those well-treated, are at increased risk for heart disease when compared to the general population. Two hormones called aldosterone and brain natriuretic peptide (BNP), which have been shown to be abnormal in HIV, may be associated with inflammation as well as early changes in structure and function of the heart. This study is being conducted to evaluate whether therapies to block aldosterone and increase BNP levels may reduce the burden and progression of heart failure to improve cardiovascular health.

Timeline

Start
2020-09-11
Primary completion
2025-07-09
Completion
2025-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacubitril-Valsartan Unknown Oral